Overcoming five main challenges to targeting hematologic malignancies.

The development and application of chimeric antigen receptor (CAR) T-cell therapies have changed the treatment landscape of hematologic malignancies. While there are currently FDA approved products for their use in relapsed or refractory B-cell and plasma cell malignancies, ongoing research efforts strive to target difficult to treat antigens and diseases. In this review, we discuss five main challenges involving CAR-T cell products in hematologic malignancies. Additionally, we propose mechanisms to overcome these challenges that monitor adverse effects, improve universal access, enhance manufacturing platforms, and advance commercialization with the goal of optimal patient care.